Overview
Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males
Status:
Completed
Completed
Trial end date:
2019-05-01
2019-05-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
The purpose of this study is to evaluate sites of gut absorption of BMS-986165 in malesPhase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Bristol-Myers SquibbTreatments:
BMS-986165
Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, pleasevisit www.BMSStudyConnect.com
Inclusion Criteria:
- Body mass index of 18.0 to 32.0 kg/m2, inclusive, and weight ≥ 50 kg, at screening
- Estimated glomerular filtration rate (eGFR) > 80 mL/min/1.732 calculated with the
Chronic Kidney Disease Epidemiology Collaboration formula
Exclusion Criteria:
- Any significant acute or chronic medical illness
- Current or recent (within 3 months of study drug administration) disease of the gut
that, in the opinion of the Investigator or Medical Monitor, could impact upon the
absorption of study drug
- Acute diarrhea, or constipation within 3 weeks prior to randomization
- Any major surgery within 4 weeks of randomization
Other protocol defined inclusion/exclusion criteria could apply